Expertise in
6
conditions

Robert Weinkove

Auckland, AUK, NZ 
Expertise in
6
conditions
Auckland, AUK, NZ 

Overview

Robert Weinkove practices practicing medicine in Auckland, New Zealand.

Mr. Weinkove is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Agranulocytosis, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 86 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Auckland, AUK, New Zealand
Other Locations
Wellington, WGN, New Zealand
Newtown, WGN, New Zealand
Dunedin, OTA, New Zealand

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Enrollment Status: Completed
Publish Date: March 30, 2025
Intervention Type: Drug
Study Drugs: Zanubrutinib, Ibrutinib
Study Phase: Phase 3
A Phase I Dose Escalation Trial of Autologous Third-generation Anti-CD19 Chimeric Antigen Receptor T-cells (WZTL-002) for Relapsed and Refractory B-cell Lymphomas
A Phase I Dose Escalation Trial of Autologous Third-generation Anti-CD19 Chimeric Antigen Receptor T-cells (WZTL-002) for Relapsed and Refractory B-cell Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: August 21, 2024
Intervention Type: Biological, Drug
Study Drugs: WZTL002-1 (1928T2z CAR-T cells), Cyclophosphamide and Fludarabine Lymphodepleting Chemotherapy
Study Phase: Phase 1
View 1 Less Clinical Trial

86 Total Publications

Blood tests to predict CAR T-cell toxicity and efficacy.
Blood tests to predict CAR T-cell toxicity and efficacy.
Journal: Blood advances
Published: January 13, 2026

Frequently Asked Questions about Robert Weinkove

Is Robert Weinkove a top-rated expert for Small Lymphocytic Lymphoma (SLL)?

MediFind is an objective health platform that identifies experts based on real-world data. Robert Weinkove is classified as an Distinguished expert for Small Lymphocytic Lymphoma (SLL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Robert Weinkove participate in research or clinical trials?

Yes. Robert Weinkove has published 86 articles and abstracts on conditions like Small Lymphocytic Lymphoma (SLL). You can view a list of Robert Weinkove's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Weinkove's expertise for a condition
ConditionClose
    View All 17 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile